GlassScriptPhysician profile
Erik Wj Kokkonen
NPI 1497019905
$5,034.65
in general payments reported to CMS, 2019-2025
22 companies · $584 in 2025
The $584 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.41 · 2020: $78.31 · 2021: $214 · 2022: $891 · 2023: $1,878 · 2024: $1,375 · 2025: $584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.79 | 2020-2025 | |
| Janssen Biotech, INC. | $739.85 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $428.43 | 2022-2024 | Sotyktu |
| Pfizer INC. | $378.36 | 2022-2025 | |
| Incyte Corporation | $336.30 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $278.22 | 2022-2024 | Taltz, Olumiant, Zepbound |
| Regeneron Healthcare Solutions, INC. | $277.07 | 2020-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $271.09 | 2022-2025 | |
| Amgen INC. | $213.85 | 2022-2024 | Otezla |
| Dermavant Sciences, INC. | $158.08 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $131.16 | 2019-2025 | Odomzo, Blu-U |
| Genzyme Corporation | $102.66 | 2022-2025 | |
| Ucb, INC. | $93.05 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.14 | 2023-2024 | Spevigo |
| Organon LLC | $72.12 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $51.59 | 2024 | Elekta Medical Linear Accelerator |
| Galderma Laboratories, L.P. | $38.25 | 2023-2025 | Nemluvio |
| Fresenius Kabi USA, LLC | $21.77 | 2023 | |
| Genentech USA, INC. | $21.59 | 2023 | Erivedge |
| Leo Pharma INC. | $15.89 | 2023 | Adbry |
| Helsinn Therapeutics (U.S.), INC. | $15.00 | 2021 | |
| Arcutis Biotherapeutics, INC. | $14.39 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Kokkonen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.